Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response

Xinna Zhang, Lin Lin, Huarong Guo, Jianhua Yang, Stephen N. Jones, Aart Jochemsen, and Xiongbin Lu

1Department of Biological Sciences and 2Center for Colon Cancer Research, University of South Carolina, Columbia, South Carolina; 3Texas Children’s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas; Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts; and 4Department of Molecular and Cell Biology, Leiden University Medical Center, Leiden, the Netherlands

Abstract

MdmX and Mdm2 regulate p53 tumor suppressor functions by controlling p53 transcriptional activity and/or stability in cells exposed to DNA damage. Accumulating evidence indicates that ATM-mediated phosphorylation and degradation of Mdm2 and MdmX may be the initial driving force that induces p53 activity during the early phase of the DNA damage response. We have recently determined that a novel protein phosphatase, Wip1 (or PPM1D), contributes to p53 regulation by dephosphorylating Mdm2 to close the p53 activation loop initiated by the ATM/ATR kinases. In the present study, we determine that Wip1 directly dephosphorylates MdmX at the ATM-targeted Ser403 and indirectly suppresses phosphorylation of MdmX at Ser342 and Ser367. Wip1 inhibits the DNA damage–induced ubiquitination and degradation of MdmX, leading to the stabilization of MdmX and reduction of p53 activities. Our data suggest that Wip1 is an important component in the ATM-p53-MdmX regulatory loop. [Cancer Res 2009;69(20):7960–8]

Introduction

The wild-type p53-induced phosphatase 1, Wip1 (or PPM1D), is a member of the type 2C serine/threonine phosphatases (PP2C δ). Wip1 has oncogenic activities and can cooperate with other known oncoproteins to induce transformation of rodent primary fibroblasts (1, 2). Furthermore, the Wip1 gene is present in amplified copy numbers and is overexpressed in many human cancer types, including breast carcinomas, ovarian clear cell adenocarcinomas, neuroblastomas, pancreatic adenocarcinomas, gastric carcinomas, and medulloblastomas (1, 3–8). In rodent primary fibroblast transformation assays, Wip1 cooperates with known oncoproteins to induce transformation foci (2). Recent identification of Wip1 targets has provided mechanistic insights into its oncogenic functions. Wip1 acts as a homeostatic regulator of the DNA damage response by dephosphorylating ATM/ATR target proteins. Three of the Wip1 targets now identified are kinases that phosphorylate and activate p53 (Chk1, Chk2, and p38MAPK; refs. 9–11). In addition, Wip1 targets p53 itself at Ser15, implicating Wip1 as a major inhibitor of p53 function (11). Studies on Wip1 null mouse embryonic fibroblasts (MEF) corroborate this Wip1 inhibitory function. MEFs lacking Wip1 displayed reduced proliferation, enhanced p53 transcriptional activity, and an enhanced DNA damage–induced G1 checkpoint (12).

Negative regulation of p53 is manifested chiefly through Mdm2-mediated p53 ubiquitination and proteasomal degradation. Interestingly, p53 not only transcriptionally regulates genes involved in cell cycle arrest or apoptosis, but also induces expression of its negative regulator, Mdm2. Thus, p53 and Mdm2 participate in an autoregulatory feedback loop (13). MdmX (or Mdm4) was identified as a p53-binding protein that was related to Mdm2, but lacked ubiquitin-ligase function. Similar to Mdm2, MdmX deficiency in mice causes early embryonic lethality rescued by p53 loss (14, 15). Thus, MdmX and Mdm2 have nonredundant roles in the regulation of p53, and recent in vitro and in vivo studies have suggested that Mdm2 controls p53 transcriptional activity by regulating p53 protein stability, whereas MdmX functions as a p53 transcriptional inhibitor without altering p53 levels (13).

Recent results from our laboratory showed that Wip1 interacts with and dephosphorylates Mdm2 at serine 395, a site phosphorylated by the ATM kinase (16). Dephosphorylated Mdm2 has increased stability and affinity for p53, facilitating p53 ubiquitination and degradation. Thus, Wip1 may act as a gatekeeper in the Mdm2-p53 regulatory loop by stabilizing Mdm2 and promoting Mdm2-mediated proteolysis of p53 (17). Several groups reported that MdmX is also phosphorylated and destabilized in response to DNA damage stress. Three phosphorylation sites identified are Ser342, Ser367, and Ser403 (18–20). Although Ser403 is directly phosphorylated by ATM, the other two sites are phosphorylated by Chk1 and Chk2, two kinases that are well-established cell cycle regulators known to be activated by ATM/ATR (18–21). Here, we present evidence that Wip1 specifically dephosphorylates MdmX at Ser403 and indirectly suppresses phosphorylation of MdmX at Ser342 and Ser376. Wip1 increases the stability of MdmX and extends its half-life. Our results suggested that Wip1 suppression of p53 signaling by augmenting the stability of MdmX may be an important component of its oncogenicity.

Materials and Methods

Cell lines and cell culture. U2OS (p53 wild-type) cell line is a human osteosarcoma line that was obtained from the American Type Culture Collection. Primary p53+/-, p53–/-, Mdm2+/-, and p53–/–/Mdm2–/– MEFs were harvested and cultured as previously described (12–22, 23). The A-T cell line GM9067 was obtained from the Coriell Cell Repositories. To obtain cells stably expressing MdmX, expression vector expressing HA-tagged wild-type or mutant human MdmX was transfected into U2OS cells, and stable cells were selected with 1,000 µg/mL G-418. Positive colonies were isolated, amplified, and checked for expression of HA-MdmX protein individually.
**Plasmid constructs.** Expression vectors expressing mouse and human Wip1 used in these experiments have been previously described (24). The p21-Luciferase construct was obtained from Dr. G. Lozano (M.D. Anderson Cancer Center, Houston, Texas). The vectors expressing wild-type and mutant MdmX were previously described (20). Wip1 shRNA expression vector (RHS3979-9571552) was purchased from Openbiosystems.

**Cell transfection with plasmid DNA.** Cells were transfected with plasmid DNA by Lipofectamine and Plus reagents (for transformed cell lines, Invitrogen) or Lipofectamine 2000 reagent (for MEFs, Invitrogen). Transfection experiments were performed following the instruction manuals provided with reagents.

**Luciferase assays.** Cells were cotransfected with a p53 expression vector, p21-Luciferase, Renilla luciferase, and Wip1 expression vector. Cells were harvested and lysed. Luciferase activity was measured using a Turner 20/20n luminometer and normalized to Renilla luciferase and cell number according to the instructions provided with the dual-luciferase assay kit (Promega).

**Western blot analysis, antibodies, and purified proteins.** Immunoprecipitations, Western blot analysis, and immunoprecipitation–Western blot analyses were performed by standard methods described previously (11). Anti-actin, anti-ubiquitin, horseradish peroxidase (HRP)–anti-goat IgG, HRP–anti-rabbit IgG, and HRP–anti-mouse IgG were purchased from Santa

---

**Figure 1.** Wip1 interacts with and dephosphorylates MdmX. A, the effects of overexpressed Ser/Thr protein phosphatases on the levels of MdmX. U2OS cells were transfected with control or phosphatase expression vector, treated by NCS (500 ng/mL), and then harvested 2 h after treatment. Levels of MdmX were detected by immunoblotting and quantitated according to the intensity of MdmX bands. B, Wip1 inhibits the phosphorylation of MdmX. U2OS cells were transfected with control or Wip1 expression vector. Cell lysates were harvested 2 h after NCS (500 ng/mL) and MG132 (25 mmol/L, proteasomal inhibitor) treatment. Protein levels were determined by immunoblotting. C, Wip1 interacts with wild-type and mutant MdmX. Immunoprecipitates (IP) from U2OS cell lysates using control or anti-MdmX antibody were analyzed by immunoblotting using anti-Wip1 antibody (top left). A reciprocal experiment using Wip1-containing immunoprecipitates confirmed the Wip1-MdmX interaction (bottom left). U2OS cells were also transfected with vector DNA expressing wild-type or mutant MdmX with three phosphorylation sites (S342, S367, and S403) mutated to alanines (right). D, Wip1 inhibits the phosphorylation of MdmX and directly dephosphorylates MdmX pSer403 in vitro. Phospho-specific MdmX antibodies were used to measure the effects of Wip1 on the phosphorylation of MdmX (left). Phosphopeptides from p38 MAP kinase [pT180, positive control (pos. ctrl)], UNG2 [pT31, negative control (neg. ctrl)], and MdmX (pS342, pS367, or pS403) were incubated with purified Wip1 proteins in in vitro phosphatase assays. Reactions on MdmX (pSer403) were also performed in the absence of magnesium or peptide, or in the presence of okadaic acid (right).
Cruz; Anti-HA and anti-MdmX (from Bethyl Laboratories for human MdmX and from Sigma-Aldrich for mouse MdmX) were purchased from Bethyl Laboratories; Anti-Wip1 was purchased from Abgent; anti-MdmX, anti-MdmX, and anti-MdmX were generated and described previously (18, 20).

**Protein stability measurement.** Cell stably expressing wild-type or mutant HA-MdmX were transfected with Wip1 or control expression vector DNA. Twenty-four hours after transfection, cells were treated with 500 ng/mL neocarzinostatin (NCS) and 50 μg/mL cyclohexamide. Cells were harvested at indicated time points after treatment, and cell lysates were immunoblotted with anti-HA antibody. Levels of MdmX at each time point were quantitated by phosphorimager for MdmX bands on immunoblots.

**In vitro phosphatase assays.** The in vitro phosphatase assays and control peptide sequences have been described previously (24). MdmX phosphopeptides were custom synthesized by New England Peptide. Their sequences are as follows: MdmX (pS342): Ac-LTHSLpSTSDT-amide; MdmX (pS367): Ac-CRRTIpSAPVVVR-amide; MdmX (pS403): Ac-AHSSEpSQETIS-amide.

**Ubiquitination assays.** Cells were treated with proteasomal inhibitors MG101 (25 μmol/L) and MG132 (25 μmol/mL). Six hours after treatment, cells were harvested and lysed in the lysis buffer [20 mmol/L HEPES (pH 7.4), 240 mmol/L NaCl, 0.1 mmol/L EDTA, 0.5% TritonX-100, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L DTT, and Complete Mini protease inhibitor tablet from Roche]. Ubiquitinated MdmX were immunoprecipitated with anti-HA antibodies, and then were Western blot analyzed with anti-ubiquitin antibody.

**Results**

Wip1 affects the DNA damage–induced phosphorylation of MdmX. Recent studies have reported that MdmX is destabilized by the DNA damage–induced phosphorylation (18, 20, 21). To determine if phosphorylation and destabilization of MdmX is reversed by protein phosphatases, we generated a library of
mammalian expression vectors encoding 23 protein serine/threonine phosphatases (or catalytic subunits if multimeric) including 11 PPPs and 12 PPMs (25). Using this library, we screened for protein phosphatases that increase MdmX levels in human osteosarcoma U2OS cells treated with DNA-damaging agent, NCS. Five of 23 phosphatases were shown to increase MdmX protein levels in the DNA damage response, one of which was the Wip1 phosphatase (Fig. 1A). We then examined the phosphorylation of MdmX in U2OS cells with overexpression or knockdown of Wip1. Levels of global phosphorylated MdmX were increased in cells treated with NCS, consistent with previous reports (18). In similar amounts of total MdmX, overexpression of Wip1 significantly reduced phosphorylation of MdmX, whereas reducing endogenous Wip1 levels increased MdmX phosphorylation (Fig. 1B). The interaction between Wip1 and MdmX was detected in the reciprocal immunoprecipitation Western blot analyses. The results showed that endogenous Wip1 binds to endogenous MdmX (Fig. 1C, left). To date, three DNA damage–induced phosphorylation sites on MdmX have been identified: Ser342, Ser367, and Ser403 (18–20). We further examined whether phosphorylation of MdmX contributes to the MdmX-Wip1 interaction. A mutant form of MdmX with all of the three phosphorylation sites mutated to alanines retained the same level of Wip1-binding capacity as wild-type MdmX, suggesting that phosphorylation is not essential for MdmX’s binding to Wip1 (Fig. 1C, right). We also tested whether Wip1 affects the phosphorylation of each serine site by using phospho-specific antibodies and cell lysates containing similar amounts of MdmX. Phosphorylation of all three sites was remarkably inhibited by Wip1 overexpression, suggesting that Wip1 may be responsible for the dephosphorylation of MdmX (Fig. 1D, left). To determine whether Wip1 directly dephosphorylates MdmX, we performed in vitro phosphatase assays by incubating purified Wip1 proteins with MdmX-derived phosphopeptides. The MdmX Ser403 phosphopeptide was dephosphorylated by Wip1, and the Wip1 activity on this phosphopeptide was magnesium dependent and okadaic acid insensitive, consistent with the known properties of the type 2C phosphatase (Fig. 1D, right). Although Wip1 inhibited the phosphorylation of MdmX at Ser342 and Ser367 in vivo, the MdmX peptides containing pSer342 or pSer367 were not dephosphorylated by Wip1 in the phosphatase assays, indicating that Wip1 regulates these two phosphorylation sites indirectly.

**Wip1 augments MdmX stability after DNA damage.** MdmX stability is regulated by ubiquitination and proteasomal degradation (26). We tested whether Wip1 regulates MdmX levels in cells in the presence of DNA damage stress. ATM-mediated phosphorylation of MdmX at Ser403 was increased immediately after NCS treatment, and levels of MdmX were reduced simultaneously in cells. Wip1 overexpression attenuated MdmX phosphorylation and increased MdmX levels, whereas knockdown of Wip1 by its shRNA
enhanced MdmX phosphorylation and accelerated MdmX degradation (Fig. 2A). Wip1-mediated stabilization of MdmX was further confirmed in primary Wip1+/+ and Wip1−/− MEFs harvested from littermate embryos. MdmX was remarkably more unstable in Wip1−/− MEFs than in Wip1+/+ MEFs in the presence of NCS treatment. Inhibiting ATM and ATR kinases by CGK733 dramatically enhanced the stability of MdmX in Wip1+/+ MEFs, but not in Wip1−/− MEFs, suggesting the regulation of MdmX by Wip1 is dependent on the kinase activity of ATM/ATR (Fig. 2B). We then measured the half-life of endogenous MdmX with or without overexpressed Wip1. The half-life of MdmX in unstressed cells was as long as 44 hours, which was dramatically reduced to 24 minutes in NCS-treated cells. Altered Wip1 levels had no significant effects on the stability of MdmX in the absence of DNA damage stress. However, overexpressed Wip1 extended the half-life of MdmX to 51 minutes in the stressed cells, whereas knockdown of Wip1 further decreased MdmX stability with the half-life about 12 minutes (Fig. 2C and D). These results showed that Wip1 stabilizes MdmX in the DNA damage response.

We next tested whether Wip1 affects the ubiquitination of MdmX. To this end, we generated U2OS cell lines that stably express HA-tagged wild-type or mutant MdmX, of which one or more of the DNA damage–targeted serines are mutated into alanines, mimicking nonphosphorylated forms of MdmX. We examined the effects of altered Wip1 levels on MdmX ubiquitination. In cells expressing wild-type MdmX, overexpression of Wip1 lowered MdmX ubiquitination, whereas silencing Wip1 by shRNA enhanced MdmX ubiquitination compared with control cells.
Ubiquitination of MdmX (S403A) was also decreased by Wip1, but the effect of Wip1 was significantly diminished compared with that on the wild-type MdmX, suggesting that Ser403 is one of the major phosphorylation sites regulated by Wip1. As expected, much lower levels of ubiquitination were observed on the triple phosphorylation mutant MdmX (S342/367/403A). Altered levels of Wip1 had no effects on the ubiquitination of this mutant MdmX (Fig. 3A and B).

Wip1 stabilization of MdmX is dependent on the phosphorylation of MdmX. We further examined to what extent Wip1 promotes the stability of MdmX. We assessed the half-lives of wild-type and mutant forms of MdmX that were stably expressed as HA-tagged proteins in U2OS cells (Fig. 4A and B). The half-life of wild-type HA-MdmX was about 26 minutes and was extended to 53 minutes in the presence of overexpressed Wip1, which is consistent with the half-life of endogenous MdmX (Fig. 2D). MdmX (S367A) and MdmX (S403A) both had prolonged half-lives, of about 51 and 41.5 minutes, respectively, which is likely due to their partial defective phosphorylation state in the DNA damage response. Overexpressed Wip1 augmented the stability of mutant MdmX to a lesser extent compared with that of wild-type MdmX. In the presence of overexpressed Wip1, the half-lives of MdmX (S367A) and MdmX (S403A) were increased only by 26.5% and 44.6% compared with the control, in contrast to 104% of increase observed in the half-life of wild-type MdmX. Interestingly, if all of the three phosphorylation sites were mutated to alanine in MdmX (S342/376/403A), MdmX became extremely stable with a half-life about 80 minutes. Wip1 had no significant effects on the stability of the triple mutant MdmX, indicating that these sites are probably the major Wip1 regulated phosphorylation sites on MdmX. These results are also consistent with the ubiquitination assays (Fig. 3).

Wip1 was shown to inactivate several key kinases in DNA damage signaling pathway, including p38MAPK, Chk1, and Chk2 (9–11). Because the phosphorylation of Ser342, Ser367, and Ser403 is mediated by ATM or its downstream targets—Chk1 and Chk2, we hypothesized that Wip1 regulates MdmX degradation in an ATM-dependent manner. An ATM-deficient human fibroblast cell line (GM9607) was used to determine whether increased levels of Wip1 promote MdmX accumulation in the absence of functional ATM signaling (Fig. 4B). MdmX remained relatively stable in NCS-treated GM9607 cells regardless of Wip1 levels. No significant reduction on the MdmX levels was observed during 4-hour postdamage. When ATM was reintroduced into these cells, MdmX became more unstable following NCS treatment. Addition of Wip1 helped to stabilize MdmX in the ATM-containing cells, indicating that Wip1 stabilizes MdmX by reversing the destabilizing effects of ATM-mediated phosphorylation. It should be noted that overexpression of Wip1 slightly increased the levels of MdmX even in GM9607 cells (in particular, at times 0 and 1 hour after treatment). Although ATM plays a primary role in the DNA damage response to double-stranded DNA breaks, ATR also contributes to the process by activating some of the common ATM/ATR targets.

Figure 5. Wip1 regulates the activity of p53 in an Mdm2- and MdmX-dependent manner. A, effect of Wip1 on MdmX is dependent on Mdm2. MEFs were transfected with control or Wip1 expression vector, treated with NCS (200 ng/mL) and cyclohexamide (100 μg/mL), harvested, and immunoblotted as indicated. B, p53 activity shown by p21 induction is inhibited by Wip1 in an Mdm2- and MdmX-dependent manner at the early stage of DNA damage response. MEFs were transfected with p53 expression vector, along with Wip1 or control expression vector. Cells were treated with NCS (200 ng/mL) and Nutlin-3 (10 μmol/L) as indicated. Eighteen hours after treatment, cells were assayed for relative luciferase activity (versus nontreated cells transfected with control vector DNA in each set) to assess the transcriptional activity of p53. Columns, mean of three independent experiments; bars, SD. Two group comparisons were analyzed by Student’s t test.

www.aacrjournals.org 7965 Cancer Res 2009; 69: (20). October 15, 2009
In ATM-deficient cells, Wip1 may affect the stability of MdmX by inhibiting these ATR targets, such as Chk1 and Chk2. MdmX and Mdm2 are promptly destabilized immediately in DNA damage–stressed cells, resulting in a rapid induction of p53 (18). In Fig. 4C, the levels of Mdm2 and MdmX in U2OS cells bottomed at 1 and 4 hours after 5 Gy of ionizing radiation, respectively, whereas the levels of Wip1 seems to be induced in a delayed pattern. Its level only has a mild increase 2 hours after ionizing radiation, and then increases gradually to the peak around 8 to 12 hours after damage. This pattern is consistent with the role of Wip1 as a homeostatic regulator in stressed cells. As expected, overexpression of Wip1 disturbed this homeostatic regulation, resulting in a high stability of MdmX at the early stage of DNA damage response (0–8 hours).

**Wip1 inhibition of p53 is dependent on MdmX and Mdm2.** Previous study showed that Mdm2 is a critical E3 ubiquitin ligase that targets MdmX for degradation in cells (29). Here, we attempted to examine whether Wip1 regulates the stability of MdmX in an Mdm2-dependent manner. First, we examined the stability of MdmX in the presence or absence of Mdm2. In cyclohexamide-treated p53−/− Mdm2+/+ MEFs, MdmX showed a significantly higher stability in Wip1-overexpressing cells than in control cells. In contrast, MdmX was extremely stable in both of the control and Wip1-overexpressing p53−/− Mdm2−/− cells, suggesting the effect of Wip1 on MdmX may be mediated by Mdm2 in cells (Fig. 5A). We next tested whether Wip1 regulates the activity of p53 in the presence or absence of Mdm2 or MdmX. As both Mdm2 and MdmX knockout mice are embryonic lethal in the presence of wild-type p53 (14, 15, 22), we tested the Wip1 effects in p53−/−, p53−/− Mdm2−/−, or p53−/− MdmX−/− MEFs that all lacked functional p53. These MEFs were transfected with p53 and with or without Wip1. Levels of p53 and p53-induced p21 were measured 4 hours after NCS treatment. Consistent with previous reports (11, 17), Wip1 overexpression inhibits the DNA damage–mediated induction of exogenous p53 activity in p53−/− MEFs. However, effects of Wip1 on p21 induction were remarkably reduced in p53−/− MdmX−/− MEFs and p53−/− Mdm2−/− MEFs. The results suggested that both Mdm2 and MdmX are important mediators for Wip1 in regulating the transcriptional activity of p53 (Fig. 5B). To confirm and better quantitate the effects of Wip1 on p53 induction, we performed a luciferase reporter assay in the above MEFs. Cells were transfected with p53 expression vector, p21-luciferase expression vector, and either control or Wip1 expression vector. Cell growth was not much influenced by Wip1 overexpression during the experimental period and the luciferase activity peaks around 18 hours after NCS treatment (Supplementary Fig. S1). The results showed that Wip1 negatively regulates p53 specifically in the DNA damage response (Fig. 5C). Nutlin-3 is a potent Mdm2 inhibitor that interferes with p53-Mdm2 interaction, and Nutlin-3 treatment of p53−/− cells profoundly induced the activity of exogenous p53. This increase in activity was not inhibited by overexpressed Wip1. Moreover, loss of Mdm2 also abolished effects of Wip1 on p53 activity, as shown in p53−/− Mdm2−/− cells. These results confirmed that the effects of Wip1 on MdmX are at least partly dependent on Mdm2, suggesting that Wip1-mediated stabilization of MdmX is likely Mdm2 dependent. We further examined the effects of Wip1 in the p53−/− MdmX−/− cells. Wip1 overexpression suppressed p53 activity in the stressed cells even in the absence of MdmX, but the reduction of p53 activity in the p53−/− MdmX−/− cells was relatively modest (33%) in contrast with a more profound reduction (61%) observed in the

![Figure 6](image-url)

**Figure 6.** Wip1 interferes with Mdm2-MdmX interaction but enhances USP7-MdmX interaction. A, phospho-mutant forms of MdmX have reduced binding ability with Mdm2 but have enhanced binding activity with USP7. 293 HEK cells were transfected with HA-tagged wild-type or mutant MdmX expression vector, treated with NCS (200 ng/mL), and harvested 2 h after treatment. Cell lysates were immunoprecipitated with anti-Mdm2 or anti-USP7 antibody, and Western blotting was performed to examine the binding activity of MdmX with Mdm2 and USP7 (Supplementary Fig. S1). The results showed that Wip1 negatively regulates p53 specifically in the DNA damage response (Fig. 5C). Nutlin-3 is a potent Mdm2 inhibitor that interferes with p53-Mdm2 interaction, and Nutlin-3 treatment of p53−/− cells profoundly induced the activity of exogenous p53. This increase in activity was not inhibited by overexpressed Wip1. Moreover, loss of Mdm2 also abolished effects of Wip1 on p53 activity, as shown in p53−/− Mdm2−/− cells. These results confirmed that the effects of Wip1 on MdmX are at least partly dependent on Mdm2, suggesting that Wip1-mediated stabilization of MdmX is likely Mdm2 dependent. We further examined the effects of Wip1 in the p53−/− MdmX−/− cells. Wip1 overexpression suppressed p53 activity in the stressed cells even in the absence of MdmX, but the reduction of p53 activity in the p53−/− MdmX−/− cells was relatively modest (33%) in contrast with a more profound reduction (61%) observed in the

![Diagram](image-url)
Our previous studies have shown that Mdm2 is dephosphorylated and stabilized by Wip1 (17). Because Mdm2 seems to be the primary E3 ligase for MdmX degradation (29), it is presently unclear how Wip1 stabilizes both Mdm2 and MdmX during the DNA damage response. One hypothesis is that phosphorylation of MdmX changes its binding capacity to Mdm2 and ubiquitin-specific peptide 7 (USP7) that stabilizes MdmX by deubiquitination (30). Dephosphorylated MdmX seems to be a preferable substrate for USP7, but not for Mdm2. The hypothesis is supported by the binding assays shown in Fig. 6. Phosphorylation defective mutants of MdmX (single-, double-, or triple-phosphorylation mutants) have reduced binding ability with Mdm2 but have enhanced binding activity with USP7 in the DNA damage-stressed cells (Fig. 6A), suggesting that DNA damage–induced phosphorylation of MdmX may influence binding of MdmX to Mdm2 and USP7. We next assessed the effects of Wip1 on these protein interactions using cell lysates containing similar amounts of MdmX. After DNA damage, the relative amount of MdmX bound to USP7 was reduced, but this reduction was offset by overexpressed Wip1. In contrast, the Mdm2-MdmX interaction was increased after DNA damage, but was inhibited by Wip1 overexpression (Fig. 6B). Further structural information for these interactions shall provide a better understanding of Wip1 functions.

**Discussion**

Wip1 amplification and overexpression have been identified in many types of human cancers (1, 3–8). Interestingly, in cancers where Wip1 was examined, p53 mutation rates were invariably low and poorer prognoses were associated with Wip1 amplification. The infrequent nature of p53 mutations in tumors with Wip1 amplification suggests that Wip1 may promote human tumors through its ability to inhibit p53, circumventing selective pressure to mutate p53 during tumor progression. Wip1 amplification in this context is reminiscent of tumors with MdmX or Mdm2 amplification, as only a small subset of these tumors also exhibit p53 mutation (31). It was recently reported that the Wip1's negative feedback between p53 and ATM is essential for maintaining a functional DNA damage response in cells (32). Our present study reveals that Wip1 also modulates the p53 regulatory loop by regulating MdmX. DNA damage–induced phosphorylation of MdmX is inhibited by Wip1 in two ways: (a) ATM-phosphorylated Ser403 is directly dephosphorylated by Wip1; and (b) Wip1 deactivates Chk1/Chk2 by dephosphorylating their ATM-targeted sites and thus Chk1/Chk2-mediated phosphorylation of Ser342 and Ser367 on MdmX is reversed. Overexpressed Wip1 extends the half-life of wild-type MdmX. However, the effects of Wip1 were not observed with an MdmX protein of which all three phosphorylation sites were mutated, suggesting that dephosphorylation of these three sites has a synergistic effect on the stabilization of MdmX. Given its critical role in the ATM–p53 signaling pathway, Wip1 is anticipated to be regulated in response to DNA damage. Wip1 is transactivated in a p53-dependent manner (33, 34). In U2OS cells treated with ionizing radiation, both Mdm2 and MdmX are promptly destabilized after treatment (0–4 hours), resulting in a rapid induction of p53. In turn, p53 induces Mdm2 by transactivation. Wip1 seems to be induced in a delayed pattern. Wip1 protein level only has a mild increase during the first 2 hours, and then increases gradually to peak at around 8 to 12 hours post-ionizing radiation (Fig. 4C). This pattern is consistent with the role of Wip1 as a homeostatic regulator in stressed cells. In normal cells, the base level of Wip1 is about 4-fold lower than its peak level. Thus, Wip1 may need to be inhibited in the early stage of DNA damage response to facilitate rapid MdmX degradation. We observed that Wip1 is also phosphorylated in an ATM-dependent manner immediately after DNA damage (data not shown). Posttranslational modifications such as phosphorylation may modulate the activity of Wip1 or access to its targets. We propose that dephosphorylation of MdmX and Mdm2 by Wip1 increases their stability, leading to a reduction of p53 activity back to normal homeostatic levels after DNA damage is repaired (Fig. 6C).

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

Received 2/18/09; revised 8/13/09; accepted 8/18/09; published OnlineFirst 10/6/09.

**Grant support:** Grants from the American Federation for Aging Research and NIH (R01CA136599; X. Lu), and by NIH R01CA077735 (S.N. Jones).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs, Jiandong Chen and Michael Kastan for providing plasmids and antibodies, and Dr. Alan Waldman and Dr. Lawrence Donehower for helpful discussions.

**References**

Phosphorylation and Degradation of MdmX Is Inhibited by Wip1 Phosphatase in the DNA Damage Response

Xinna Zhang, Lin Lin, Huarong Guo, et al.

Cancer Res  Published OnlineFirst October 6, 2009.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-0634

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/09/24/0008-5472.CAN-09-0634.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.